Alec Stranahan
Stock Analyst at B of A Securities
(0.51)
# 3,921
Out of 4,846 analysts
30
Total ratings
35%
Success rate
-30.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $16.19 | +159.42% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.74 | +153.16% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $5.59 | +168.34% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.01 | +256.63% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $0.97 | +1,028.32% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.43 | +250.88% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.39 | +151.05% | 2 | Nov 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $40.65 | +35.30% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $7.07 | +154.60% | 3 | Jun 14, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $125.36 | +11.68% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $8.58 | +389.51% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $35.75 | -83.22% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.57 | +218.47% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $46.67 | -3.58% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $16.19
Upside: +159.42%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.74
Upside: +153.16%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.59
Upside: +168.34%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.01
Upside: +256.63%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $0.97
Upside: +1,028.32%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.43
Upside: +250.88%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.39
Upside: +151.05%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $40.65
Upside: +35.30%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $7.07
Upside: +154.60%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $125.36
Upside: +11.68%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $8.58
Upside: +389.51%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $35.75
Upside: -83.22%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.57
Upside: +218.47%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $46.67
Upside: -3.58%